Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ABEO | DEFA14A | neutral | 2/10 | Abeona Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) on May 4, 2026, likely supplementin | May 4, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Insider trading cluster at United Therapeutics shows minimal open-market sales totaling ~$1.92M against a $24.2B market | May 4, 2026 |
| UTHR | 144 | neutral | 3/10 | Officer James Edgemond files Form 144 to sell 148,750 shares ($84.8M) from option exercises under a pre-arranged 10b5-1 | May 4, 2026 |
| CATX | 8-K | neutral | 2/10 | Perspective Therapeutics filed an 8-K reporting that it posted a presentation with estimated cash, cash equivalents, and | May 4, 2026 |
| CRSP | 8-K | bearish | 5/10 | CRISPR Therapeutics reported Q1 2026 EPS of -$1.28, missing consensus of -$1.14 by 12.3%. Total revenue of $1.5M was up | May 4, 2026 |
| VTRS | 8-K | neutral | 3/10 | Viatris CFO Theodora Mistras voluntarily departs for another opportunity; CAO Paul Campbell appointed interim CFO effect | May 4, 2026 |
| KPTI | S-3 | neutral | 3/10 | Karyopharm filed an S-3 shelf registration for the resale of up to 8,843,036 shares by RA Capital Healthcare Fund, consi | May 4, 2026 |
| KPTI | S-3 | bearish | 7/10 | Karyopharm filed a $400M universal shelf registration (including a $100M ATM) representing ~202% of its $198M market cap | May 4, 2026 |
| SABSW | 8-K | neutral | 3/10 | SAB Biotherapeutics entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for cl | May 4, 2026 |
| CLLS | 6-K | neutral | 2/10 | Cellectis announced it will report Q1 2026 financial results on May 11, 2026 after market close, with no conference call | May 4, 2026 |
| TRDA | 144 | neutral | 2/10 | Officer Nathan Dowden filed Form 144 to sell 15,000 shares (approx. $217,500) under a 10b5-1 trading plan. The sale is r | May 4, 2026 |
| LNZAW | 8-K | neutral | 3/10 | LanzaTech Global filed an 8-K furnishing an investor presentation that highlights commercial progress, cost reductions, | May 4, 2026 |
| CAPR | CLUSTER | neutral | 2/10 | Two insiders (CFO and EVP/General Counsel) exercised stock options and sold an aggregate of 50,000 shares at ~$31.70 eac | May 4, 2026 |
| IFRX | 6-K | neutral | 3/10 | InflaRx announced preclinical data for izicopan showing lower reactive metabolite formation compared to avacopan in huma | May 4, 2026 |
| BHVN | S-3ASR | neutral | 3/10 | Biohaven filed an automatic shelf registration statement (S-3ASR) to register an indeterminate amount of securities for | May 4, 2026 |
| NUVB | 8-K | mixed | 6/10 | Nuvation Bio reported Q1 2026 total revenue of $83.2M (up from $3.1M YoY) and net income of $5.4M ($0.01 diluted EPS) vs | May 4, 2026 |
| AURA | 8-K | neutral | 5/10 | Aura Biosciences announced a stock repurchase agreement with Matrix Capital to buy back up to 6.9M shares at $5.64/share | May 4, 2026 |
| ANAB | PRESS-RELEASE | bullish | 7/10 | AnaptysBio reported Q4 2025 EPS of $1.58, a 268% beat vs consensus of -$0.94, indicating strong operational performance. | May 4, 2026 |
| RNTX | 8-K | bearish | 8/10 | Rein Therapeutics closed a massively dilutive underwritten public offering of 50M shares at $1.00 per share, raising ~$4 | May 4, 2026 |
| ORIC | 8-K | mixed | 4/10 | ORIC Pharmaceuticals reported Q1 2026 net loss of $35.8M ($0.34/share), missing consensus estimates of $0.31/share by 9. | May 4, 2026 |
| ACXP | S-1 | bearish | 5/10 | Acurx Pharmaceuticals filed an S-1 to register 1,300,000 shares for resale by Lincoln Park Capital Fund, LLC under an ex | May 4, 2026 |
| COAG | 8-K | neutral | 4/10 | Hemab Therapeutics completed its IPO of 19,262,500 shares at $18.00/share, raising $346.7M in gross proceeds. Concurrent | May 4, 2026 |
| ACXP | S-1 | bearish | 6/10 | Acurx Pharmaceuticals filed an S-1 to register 1,650,170 shares of common stock for resale by selling stockholders upon | May 4, 2026 |
| BHVN | 8-K | neutral | 3/10 | Biohaven reported Q1 2026 GAAP net loss of $130.5M ($0.88/share), marginally missing the Street consensus of $0.86/share | May 4, 2026 |
| TVTX | 144 | neutral | 3/10 | Elizabeth Reed, an officer of Travere Therapeutics, filed a Form 144 to sell 20,000 shares of common stock valued at app | May 4, 2026 |
| OCGN | 8-K | mixed | 6/10 | Ocugen announced a private offering of $115M convertible senior notes due 2034 (plus $15M option), intending to use ~$32 | May 4, 2026 |
| PRAX | PRESS-RELEASE | neutral | 1/10 | Praxis Precision Medicines, Inc. announced it will report its Q1 2026 results on May 7, 2026. | May 4, 2026 |
| FBLG | PRESS-RELEASE | neutral | 3/10 | FibroBiologics announced preclinical results suggesting that its human dermal fibroblast spheroid treatment may reduce i | May 4, 2026 |
| CYTK | PRESS-RELEASE | neutral | 3/10 | Cytokinetics announced it will report topline results from its ACACIA-HCM trial (aficamten in non-obstructive HCM) on Ma | May 4, 2026 |
| CHRS | PRESS-RELEASE | neutral | 1/10 | Coherus Oncology, Inc. announced it will report its Q1 2026 results on May 11, 2026. | May 4, 2026 |